January 27th 2023
The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography
April 20th 2022This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.
Read More
Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL
April 13th 2022This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.
Read More
Mixed QOL Findings Following Treatment Highlight Need for BC Support Services
April 9th 2022This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.
Read More
CDK4/6 Inhibitors, SERDs, and More in NCCN Talk on Breast Cancer Updates
April 1st 2022NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Read More
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
March 23rd 2022This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Read More
Considerations to Increase Rates of Breast Cancer Screening Across Populations
Authors from the Community Oncology Alliance and Avalere Health present data that show breast cancer screening rates recovered more slowly among some racial/ethnic groups following on the onset of the COVID-19 pandemic.
Read More
A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women
March 10th 2022This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Read More
Dr Debra Patt Discusses Ongoing Pandemic-Related Delays in Cancer Screenings
March 2nd 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.
Read More
Possibility of Breast Cancer Overdiagnosis Should Inform Mammography Decisions
February 28th 2022This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.
Read More
Dr Funmi Olopade Describes Advancements in BRCA Gene Testing
February 20th 2022Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains advancements in BRCA testing and how genetic testing has become standard of care.
Read More
Dr Kenneth Cohen: Low-Value Care Exists Across the Health Care System
February 15th 2022Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses areas where low-value care is more prevalent and the shift to high-value care.
Read More
mRNA COVID-19 Vaccines Safe Among Patients With Cancer History
February 7th 2022A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.
Read More
Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer
February 2nd 2022Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Read More
Persistent Care Variations Uncovered in New Breast Cancer Study
January 27th 2022This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.
Read More
Dr Funmi Olopade Previews Her Keynote Address for SABCS
December 6th 2021Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, previews her keynote address for the San Antonio Breast Cancer Symposium (SABCS).
Read More
Dr Funmi Olopade on WISDOM: When You Ask Women to Participate, They Sign Up
October 20th 2021The WISDOM study—Women Informed to Screen Depending On Measures of risk—was launched to test a personalized approach to screening compared to annual mammograms. Funmi Olopade, MD, FACP, is a professor of Medicine and Human Genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, and a co-investigator of WISDOM. She is an expert on understanding the etiology and genomic basis of cancer progression in diverse populations and has published extensively on both genetic and non-genetic risk factors for breast cancer. She discussed overcoming early challenges of low enrollment of Black women in the study.
Read More
The Pfizer and Moderna COVID-19 vaccines were shown to be 90% effective in preventing infection in a real-world setting; Biden administration urges states to pause reopening plans amid signs of COVID-19 surge; a lawsuit seeks to end the requirement that preventive services be provided free of charge to Americans.
Read More
The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.
Read More